MHB088C / Minghui Pharma  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MHB088C / Minghui Pharma
CTR20231298: An open-label, dose-escalation, and cohort expansion phase I/II clinical study of the safety/tolerability, pharmacokinetics, and efficacy of MHB088C for injection in patients with advanced malignant solid tumors

Ongoing
1/2
248
China
MHB088C - Minghui Pharma
Minghui Pharmaceutical (Hangzhou) Co., Ltd
 
 
NCT05652855: Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors

Not yet recruiting
1/2
48
RoW
MHB088C for Injection
Minghui Pharmaceutical Pty Ltd
Advanced or Metastatic Solid Tumors
01/26
07/26

Download Options